Law Commons^™

Trademark Hybridity And Brand Protection, Timothy Greene

Loyola University Chicago Law Journal

What’s in a word? As it turns out, quite a lot. The vast majority of words in our language, including trademarked terms, signify a variety of conceptual meanings and senses. This idea of splintered definition— described in the psycholinguistics literature as “semantic ambiguity” and offered in two flavors: “homonymy” (divergent and unrelated meanings) and “polysemy” (divergent yet related senses)—is underrepresented in trademark law. As a result, there has been a proliferation of legal doctrines that fail to accurately describe our linguistic lives, most notably including dilution and genericness. This Article draws on psycholinguistics literature on semantic ambiguity resolution to highlight …

Keeping Trolls Out Of Courts And Out Of Pocket: Expanding The Inequitable Conduct Doctrine, Giordana Mahn

Loyola University Chicago Law Journal

Patent Asserting Entities (“PAEs”), often compared with the mythological troll who lurks under a bridge it did not build, demanding payment from anybody who wants to pass, are criticized for their business model as a type of “holdup” on innovation. They wait until a practicing entity infringes, then demand payment for technology that they did not create. Their critics charge PAEs with stifling innovation, crippling research and development, and chilling healthy competition. And although the courts, Congress, and government agencies identified PAEs as an issue since their recent emergence, current patent laws are ill-suited to limit PAE litigation and combat …

Drugged Out: How Cognitive Bias Hurts Drug Innovation, Cynthia M. Ho

Faculty Publications & Other Works

No abstract provided.

Should All Drugs Be Patentable?: A Comparative Perspective, Cynthia M. Ho

Faculty Publications & Other Works

Although there has been substantial discussion of the proper scope of patentable subject matter in recent years, drugs have been overlooked. This Article begins to address that gap with a comparative perspective. In particular, this Article considers what is permissible under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), as well as how India and Canada have utilized TRIPS flexibilities in different ways to properly reward developers of valuable new drugs, while also considering the social harm of higher prices beyond an initial patent term on drugs.

This Article brings valuable insight into this area at a critical …